Standard-of-Care and Emerging Therapies for First-line Treatment of HER2+ mBC
July 20th 2023Drs McArthur and Kaklamani expand upon the standard-of care regimens used for first-line treatment of patients with HER2+ metastatic breast cancer (mBC), review clinical data supporting their use, and share excitement for upcoming data readouts on novel regimens in the space.
Data Updates and Ongoing Trials in the HER2+ Adjuvant Space
July 13th 2023Panelists discuss recent data updates on standard-of-care and emerging regimens for adjuvant treatment of HER2+ eBC, including data presented at the 2023 ASCO meeting, and highlight exciting trials in progress that have not yet read out.
Adjuvant Therapy Options in HER2+ eBC and Clinical Data on the PH Regimen
July 6th 2023Virginia G. Kaklamani, MD, DSc, and Melinda L. Telli, MD, review the various adjuvant therapy options available for patients with HER2+ early breast cancer based on stage, risk status, and whether or not they had received neoadjuvant therapy, and then touch on clinical data supporting the use of fixed-dose pertuzumab/trastuzumab (PH) in this setting.
How Does Response to Neoadjuvant Therapy Affect Prognosis and Inform Adjuvant Selection?
July 6th 2023Dr Tripathy provides clinical insight on how he assesses HER2+ eBC patient response to neoadjuvant therapy, discusses the typical prognosis for those who do or do not have residual disease, and touches on how he might approach adjuvant treatment selection for each.
Neoadjuvant Systemic Therapy for HER2+ eBC: Clinical Considerations and Evolving Modalities
June 29th 2023Panelists expand upon the most important clinical factors that inform selection amongst available systemic therapy regimens in the neoadjuvant setting of HER2+ eBC, comment on the potential for treatment de-escalation in lower-risk patients, and discuss exciting treatments on the horizon.
Kishan Discusses GI Toxicity Reduction With MRI-Guided SBRT in Prostate Cancer
April 3rd 2023Dr Kishan discusses the use of MRI-guided SBRT in prostate cancer to reduce acute genitourinary and gastrointestinal toxicity; findings from the MIRAGE study; and how MRI-guided SBRT allows for tighter planning margins, thereby reducing both physician-reported and patient-reported bowel and bladder toxicities.
Dr. Calais on the Role of PSMA-PET Imaging in mCRPC
March 10th 2023Jeremie Calais, MD, MSc, discusses the role of prostate-specific membrane antigen-PET imaging in metastatic-castrate resistant prostate cancer, and touches on the importance of integrating PSMA-PET imaging into community settings for clinical practice.
Dr. Rettig on the Evolving Use of Triplet Regimens in mHSPC
March 10th 2023Matthew Rettig, MD, discusses the evolution of triplet therapy within the landscape of metastatic hormone-sensitive prostate cancer, as well as the importance of considering key prognostic factors when utilizing this approach.